ASCO GU 2021 News : Episode 3

Video

ASCO GU 2021 News: Dr. Petros Grivas and Dr. Arlene Siefker-Radtke

Related Videos
Elizabeth Buchbinder, MD
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Guru P. Sonpavde, MD
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Marc Machaalani, MD
Kimmie Ng, MD, MPH
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Related Content
Maximilian Stahl, MD
December 18th 2024

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Smoldering Myeloma
December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Chronic Lymphocytic Leukemia | Image Credit: © LASZLO– stock.adobe.com
December 8th 2024

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL

Glenn J. Hanna, MD, director of the Center for Cancer Therapeutic Innovation (Early Drug Development Program), director of Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute; and an associate professor of medicine Harvard Medical School
December 5th 2024

PYX-201 Generates Responses and Contributes to Growing ADC Use in Solid Tumors